Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study was to examine the possible immunomodulating effects of rhIL-12 on the immune response induced by different hepatitis C virus (HCV) antigens. Freshly isolated peripheral blood mononuclear cells (PBMC) of 33 patients with chronic HCV infection were stimulated with optimal concentrations of antigens from the NS3,
NS4
, NS5, and core region of HCV in the absence or presence of interleukin-12 (IL-12). Stimulation by alpha-CD3 + alpha-CD28,
lipopolysaccharide
(
LPS
), and pokeweed mitogen (PWM) were used as controls. Proliferation and cytokine production were determined by 3H-thymidine uptake and enzyme-linked immunosorbent assay (ELISA) after 72 hr. After stimulation with antigen or antigen + IL-12, increased proliferation and production of interferon-gamma (IFN gamma) and tumor necrosis factor-alpha (TNF alpha) were observed in 23 of the 33 patients. Thus, a separation of the patients into HCV-antigen/IL-12 responders (group 1, n = 23) and HCV-antigen/IL-12 nonresponders (group 2, n = 10) was possible. Lower baseline IL-12- and
LPS
-induced IFN gamma, TNF alpha, and IL-12 production was observed in group 2 due to a possible dysfunction of accessory cells. Significant antigen-induced Th2-type cytokine (IL-4, IL-10, IL-13) production was not found. According to clinical and serological parameters, group 2 comprised mostly patients with advanced liver disease. These data suggest an HCV-related cellular immune defect in patients with hepatitis C that can be restored in most patients by IL-12.
...
PMID:Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells. 974 65